Helus Pharma Statistics
Total Valuation
Helus Pharma has a market cap or net worth of $654.62 million. The enterprise value is $488.25 million.
| Market Cap | 654.62M |
| Enterprise Value | 488.25M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026, before market open.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Helus Pharma has 73.06 million shares outstanding. The number of shares has increased by 103.06% in one year.
| Current Share Class | 73.06M |
| Shares Outstanding | 73.06M |
| Shares Change (YoY) | +103.06% |
| Shares Change (QoQ) | +4.63% |
| Owned by Insiders (%) | 15.21% |
| Owned by Institutions (%) | 39.05% |
| Float | 58.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.29 |
| P/TBV Ratio | 3.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.97, with zero debt.
| Current Ratio | 10.97 |
| Quick Ratio | 9.76 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -86.94% and return on invested capital (ROIC) is -47.63%.
| Return on Equity (ROE) | -86.94% |
| Return on Assets (ROA) | -44.38% |
| Return on Invested Capital (ROIC) | -47.63% |
| Return on Capital Employed (ROCE) | -69.00% |
| Weighted Average Cost of Capital (WACC) | 7.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.59% in the last 52 weeks. The beta is 0.62, so Helus Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +50.59% |
| 50-Day Moving Average | 11.51 |
| 200-Day Moving Average | 7.74 |
| Relative Strength Index (RSI) | 37.39 |
| Average Volume (20 Days) | 1,585,114 |
Short Selling Information
The latest short interest is 3.01 million, so 4.12% of the outstanding shares have been sold short.
| Short Interest | 3.01M |
| Short Previous Month | 3.46M |
| Short % of Shares Out | 4.12% |
| Short % of Float | 5.18% |
| Short Ratio (days to cover) | 1.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -167.05M |
| Pretax Income | -171.20M |
| Net Income | -171.20M |
| EBITDA | -166.94M |
| EBIT | -167.05M |
| Earnings Per Share (EPS) | -$4.05 |
Balance Sheet
The company has $166.37 million in cash and no debt, with a net cash position of $166.37 million or $2.28 per share.
| Cash & Cash Equivalents | 166.37M |
| Total Debt | n/a |
| Net Cash | 166.37M |
| Net Cash Per Share | $2.28 |
| Equity (Book Value) | 242.09M |
| Book Value Per Share | 3.91 |
| Working Capital | 175.13M |
Cash Flow
In the last 12 months, operating cash flow was -$140.79 million and capital expenditures $34,000, giving a free cash flow of -$140.76 million.
| Operating Cash Flow | -140.79M |
| Capital Expenditures | 34,000 |
| Depreciation & Amortization | 109,000 |
| Net Borrowing | -20.15M |
| Free Cash Flow | -140.76M |
| FCF Per Share | -$1.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Helus Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -103.06% |
| Shareholder Yield | n/a |
| Earnings Yield | -45.19% |
| FCF Yield | -21.50% |
Analyst Forecast
The average price target for Helus Pharma is $41.56, which is 363.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.56 |
| Price Target Difference | 363.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on September 19, 2024. It was a reverse split with a ratio of 1:38.
| Last Split Date | Sep 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:38 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |